Get 20% Off Market Intelligence Reports With Code ONLINE20 – Track Global Tariffs, Economic Shifts, and Sector Transformations
How Will the Market Growth Rate of the Meganuclease Genome Editing Market Impact Future Demand?
The meganuclease genome editing market size has grown rapidly in recent years. It will grow from $1.05 billion in 2024 to $1.23 billion in 2025 at a compound annual growth rate (CAGR) of 17.4%. The growth in the historic period can be attributed to increasing regulatory approvals for gene editing products, growing advancements in delivery methods for genome editing tools, increasing funding from government and private sectors, rising need for cost-effective gene editing therapies, and growing interest in treating rare and inherited diseases.
The meganuclease genome editing market size is expected to see rapid growth in the next few years. It will grow to $2.30 billion in 2029 at a compound annual growth rate (CAGR) of 17.0%. The growth in the forecast period can be attributed to rising prevalence of genetic disorders, growing investment in biotechnology and genetic research, increasing adoption of genome editing in personalized medicine, rising awareness about gene therapy solutions, and growing applications in agriculture for crop improvement. Major trends in the forecast period include technology improvements enhancing meganuclease specificity and efficiency, advancements in delivery systems for targeted gene editing, developments in high-throughput screening techniques for genome editing, technology enabling multiplex genome editing for complex genetic traits, and advancements in reducing off-target effects of meganuclease editing.
Claim your free report sample now:
What Are the Primary Growth Contributors in the Meganuclease Genome Editing Market?
The increasing prevalence of genetic diseases is expected to propel the growth of the meganuclease genome editing market going forward. Genetic diseases are disorders caused by changes or mutations in an individual's DNA that affect normal body functions. The increasing genetic diseases are due to the rising rate of consanguineous marriages, increasing the likelihood of inheriting genetic disorders. Meganuclease genome editing makes precise cuts in DNA to correct, delete, or replace defective genes, enabling targeted gene therapies with fewer off-target effects and potential cures for inherited disorders. For instance, in May 2024, according to the National Health Service, a UK-based government department, in England, approximately 17,000 people live with sickle cell disease, an inherited blood disorder, with around 250 new cases diagnosed each year. Therefore, the increasing prevalence of genetic diseases is driving the growth of the meganuclease genome editing market.
What Are the Major Product/Service Segments in the Meganuclease Genome Editing Market?
The meganuclease genome editing market covered in this report is segmented
1) By Technology: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or Cas9, Transcription Activator-Like Effector Nucleases (TALENs) Or Meganuclase-Transcription Activator-Like Effector Nucleases (MegaTALs), Zinc Finger Nucleases (ZFN), Meganuclease, Other Technologies
2) By Mode: Contract, In-house
3) By Delivery Method: Ex-Vivo, In-Vivo
4) By Application: Genetic Engineering, Cell Line Engineering, Plant Genetic Engineering, Animal Genetic Engineering, Clinical Applications, Diagnostics Development, Therapy Development, Other Applications
5) By End-User: Biotechnology And Pharmaceutical Companies, Academic And Government Research Institutes, Contract Research Organizations
Subsegments:
1) By Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or Cas9: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas9 Gene Editing, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas12, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas13
2) By Transcription Activator-Like Effector Nucleases (TALENs) Or Meganuclase-Transcription Activator-Like Effector Nucleases (MegaTALs): Genome Editing Applications, Therapeutic Applications, Agricultural Biotechnology
3) By Zinc Finger Nucleases (ZFN): Zinc Finger Nucleases Gene Editing
4) By Meganuclease: Homing Endonucleases
5) By Other Technologies: Base Editing, Prime Editing
Which Trends Are Expected to Redefine the Meganuclease Genome Editing Market Landscape?
Major companies operating in the meganuclease genome editing market are focusing on developing advanced solutions, such as in vivo gene insertion programs, to enhance therapeutic applications and expand the scope of genetic disease correction. In vivo gene insertion programs deliver genetic material directly into living organisms to insert or correct specific genes within their natural cells, enabling precise therapeutic interventions for treating genetic disorders inside the body. For instance, in May 2024, iECURE Inc., a US-based gene editing company, launched ECUR-506, an in vivo gene insertion program to treat neonatal onset ornithine transcarbamylase (OTC) deficiency, which received a fast track designation from the U.S. Food and Drug Administration (FDA). It is a gene editing therapy intended to treat neonatal onset ornithine transcarbamylase (OTC) deficiency. This therapy is designed for newborn males with severe neonatal-onset OTC deficiency and aims to restore functional OTC enzyme activity via a single intravenous infusion. It has shown a complete clinical response in the first infant treated, enabling the discontinuation of ammonia scavenger medications and a return to normal protein intake, with manageable side effects reported.
Who Are the Prominent Players in theMeganuclease Genome Editing Market?
Major companies operating in the meganuclease genome editing market are Thermo Fisher Scientific Inc., Danaher Corp., Merck KGaA, Lonza Group Ltd., Charles River Laboratories International Inc., Bio-Rad Laboratories Inc., Genscript, Takara Bio Inc., Sangamo Therapeutics Inc., Horizon Discovery, Applied StemCell Inc., Intellia Therapeutics Inc., Synthego Corporation, Editas Medicine Inc., Cellectis SA., New England Biolabs, Origene Technologies, Bluebird Bio Inc., Precision Biosciences Inc., Caribou Biosciences Inc., CRISPR Therapeutics AG.
Get the full meganuclease genome editing market report here:
What Are the Opportunities and Challenges for Meganuclease Genome Editing Market Across Regions?
North America was the largest region in the meganuclease genome editing market in 2024. The regions covered in the meganuclease genome editing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
Comments
Post a Comment